방광암의 요 생물지표에 대한 고찰
Urinary Biomarker in Bladder Cancer at Present Time
김성한, 이형호, 서호경,
소속 상세정보
김성한 ( Kim Sung-Han )
National Cancer Center Department of Urology
이형호 ( Lee Hyung-Ho )
National Cancer Center Department of Urology
서호경 ( Seo Ho-Kyung )
National Cancer Center Department of Urology
Abstract
Current standard diagnostic modality of bladder cancer is cystoscopy with/without urine cytology from patient's voided urine. Considering several cystoscopic disadvantages such as symptomatic invasiveness and operator- dependency, urinary cytology is an asymptomatic, noninvasive tool to detect exfoliated tumor cell in the urine samples. Various targeting molecules have been suggested to detect cancer cells in the urine beside the present urine cytology which has a limited diagnostic power of detection cancer cells. To augment the accuracy of diagnostic power, various supplementary urine biomarkers have been approved and under investigation in these days with different mechanisms and different targets. In this review article, we are going to discuss some urinary biomarkers approved by the U.S. Food and Drug Administration (FDA) and other non-FDA approved potential urinary markers in bladder cancer.
키워드
Urinary bladder neoplasms; Urine; Marker; Sensitivity; Specificity
원문 및 링크아웃 정보
등재저널 정보